Maria Hafez, Assistant Professor at St. Luke’s University Health Network, shared a post on X:
“From ESMO Breast Berlin, the key message in HR+/HER2. Metastatic breast cancer is no longer simply ‘what is next after CDK4/6 inhibitor?’
It is how do we sequence intelligently.
With overlapping approvals, we need to match biology to treatment:
- ESR1-mutant disease -> oral SERDs
- Endocrine-sensitive disease -> targeted combinations
- Endocrine-refractory / chemo-refractory disease -> ADCs
- Emerging space -> CDK2/4/7, KAT6 inhibitors, PROTACs, radioligand therapy
The field is moving fast, but the biggest unmet need remains clear: better biomarkers to guide selection, sequencing, and timing.
Precision in HR+ breast cancer is becoming less about adding more options, and more about choosing the right option at the right moment.”
Other articles featuring Maria Hafez on OncoDaily.